EIGR

Peginterferon Lambda-1a (Lambda)

COVID

Phase 1

Exp Date

TBD

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Peginterferon Lambda-1a in COVID-19 - Phase 1

  • ClinicalTrial.gov (NCT04331899): Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19 (COVID-Lambda)


WHAT IS THE NEXT CATALYST EVENT?

  • TBD


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA

PRESS RELEASES

PRESENTATION

MECHANISM OF ACTION / RATIONALE

  • Lambda is a well-characterized, late-stage, first in class, type Ill interferon (IFN) that stimulates immune responses critical for the development of host protection during viral infections. Lambda targets type III IFN receptors which are distinct from the type I IFN receptors targeted by IFN alfa. These type III receptors are highly expressed on hepatocytes with limited expression on hematopoietic and central nervous system cells, which may reduce off-target effects and improve tolerability of lambda. Although Lambda does not use the IFN alfa receptor, signaling through either the IFN lambda or IFN alfa receptor complexes results in the activation of the same Jak-STAT signal transduction cascade (learn more). 

Updated by HC

#EIGR, #Interferon, #Lambda, #COVID

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

EIGR - Eiger BioPharmaceutical...

Summary: Zokinvy increases survival by 2.5 years in children and young adults with Progeria Rare Pediatric Disease Priority Review Voucher issued to Eiger from FDA Eiger to host an investor call, Nove...

EIGR - Announces Results of In...

#EIGR "announced results of an investigator sponsored study of Peginterferon Lambda-1a (Lambda) in outpatients with mild and uncomplicated COVID-19.  The primary endpoint was duration of viral shed...

EIGR - Eiger Announces Peginte...

Summary: Week 48 (24 Weeks Post-Treatment) Results Presented 23% of Patients BLOQ or Undetectable HDV RNA at Week 48 55% of Patients Improved in Histology Activity Index (HAI) at Week 48 #EIGR "today...

EIGR - Eiger BioPharmaceutica...

Summary: Lambda significantly accelerated viral decline Viral clearance highly correlated with baseline viral loads- All Lambda-treated patients were below the infectivity threshold by Day 7 #EIGR "...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon